Randomized Trial of Adjuvant Human Interferon Gamma Versus Observation in High-Risk Cutaneous Melanoma: a Southwest Oncology Group Study

The Southwest Oncology Group undertook a randomized, phase III trial to test whether prognosis is improved with recombinant human interferon gamma (IFN gamma) compared with observation following definitive surgery for cutaneous melanoma. Adjuvant treatment with daily subcutaneous injection of IFN ga...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JNCI : Journal of the National Cancer Institute 1995-11, Vol.87 (22), p.1710-1713
Hauptverfasser:	Meyskens, Frank L., Kopecky, Kenneth J., Taylor, Charles W., Noyes, R. Dirk, Tuthill, Ralph J., Hersh, Evan M., Feun, Lynn G., Doroshow, James H., Flaherty, Lawrence E., Sondak, Vernon K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Antineoplastic agents Antineoplastic Agents - therapeutic use Biological and medical sciences Chemotherapy, Adjuvant Clinical trials Disease-Free Survival Female Humans Immunity (Disease) Immunotherapy Interferon Interferon-gamma - therapeutic use Male Medical sciences Melanoma - drug therapy Melanoma - pathology Middle Aged Neoplasm Staging Pharmacology. Drug treatments Skin cancer Skin Neoplasms - drug therapy Skin Neoplasms - pathology Surgery Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The Southwest Oncology Group undertook a randomized, phase III trial to test whether prognosis is improved with recombinant human interferon gamma (IFN gamma) compared with observation following definitive surgery for cutaneous melanoma. Adjuvant treatment with daily subcutaneous injection of IFN gamma at a known immunomodulatory dose was well tolerated but did not improve disease-free survival or overall survival of patients with high-risk cutaneous melanoma resected with curative intent.
ISSN:	0027-8874 1460-2105
DOI:	10.1093/jnci/87.22.1710